Dr. Reddy's receives DCGI approval for Zytorvi (toripalimab) in advanced esophageal squamous cell carcinoma in India
Dr. Reddy's said on 21 October 2026 that India's DCGI/CDSCO approved Zytorvi (toripalimab) for first-line advanced esophageal squamous cell carcinoma in India.
By ScoutQuest · · 1 min read
- Regulatory Approval
- DCGI/CDSCO approved Zytorvi (toripalimab) for first-line advanced esophageal squamous cell carcinoma in India
- Trial Efficacy - Risk Reduction
- toripalimab plus chemotherapy reduced the risk of disease or death by 42% versus chemotherapy alone
- Trial Efficacy - Overall Survival
- median overall survival of 17.7 months versus 12.9 months
- Release
- Press release
🔬 The approval is supported by the Phase 3 JUPITER-06 trial, in which toripalimab plus chemotherapy reduced the risk of disease or death by 42% versus chemotherapy alone, with median overall survival of 17.7 months versus 12.9 months.
🔬 Zytorvi was launched in India in November 2024 for recurrent or metastatic nasopharyngeal carcinoma, making India the third country after China and the United States to have access to the medicine, the release says.
📌 The IARC's GLOBOCAN 2024 India fact sheet puts esophageal cancer fourth among India's cancer deaths in 2024, at about 8.1% of the total, ESCC about 80% of cases.
Also from Dr Reddys Laboratories
Dr Reddy's files audio and video recordings of October 23, 2026 earnings call on Q2/H1 FY27 results
24 Oct 2026
Auditor's limited review reports with UDIN on Q2 and H1 results
23 Oct 2026
Board approves appointment of Akhil Ravi as Head API and Services and Senior Management Personnel
23 Oct 2026
More numbers
- Esophageal cancer share of India's cancer deaths, 2024 (IARC GLOBOCAN)8.1%
- ESCC share of esophageal cancer cases in India (IARC GLOBOCAN)80%
- JUPITER-06 risk reduction in disease or death, toripalimab plus chemotherapy42%
- Median overall survival, toripalimab plus chemotherapy (JUPITER-06)17.7 months
- Median overall survival, chemotherapy alone (JUPITER-06)12.9 months
- Countries covered by toripalimab licence with Junshi Biosciences21 countries
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.